A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)

Phase 1 Completed 87 enrolled Merck Sharp & Dohme LLC Ariad Pharmaceuticals · collab

RandomizedSingle-groupOpen-labelTreatment

Summary

This study is being done to find the best tolerated dose of ridaforolimus and dalotuzumab in patients who have advanced cancer and to observe any anti-tumor activity in these patients.

Timeline

Start: 2008-07
Primary completion: 2010-11
Completion: 2010-11

Publications

Results Di Cosimo S, Sathyanarayanan S, Bendell JC, Cervantes A, Stein MN, Brana I, Roda D, Haines BB, Zhang T, Winter CG, Jha S, Xu Y, Frazier J, Klinghoffer RA, Leighton-Swayze A, Song Y, Ebbinghaus S, Baselga J. Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial. Clin Cancer Res. 2015 Jan 1;21(1):49-59. doi: 10.1158/1078-0432.CCR-14-0940. Epub 2014 Oct 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	dalotuzumab	Monoclonal antibody	7.5 mg/kg	Intravenous
Subject	dalotuzumab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	ridaforolimus	Small molecule	10 mg	Oral
Subject	ridaforolimus	Small molecule	40 mg	Oral

A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)

Summary

Timeline

Publications

Drugs

Indications